Journal of Rheumatology最新文献_第6页

Vitamin K Antagonists for Pregnant Women With Antiphospholipid Antibodies: A Scoping Review. 用于抗磷脂抗体孕妇的维生素 K 拮抗剂：范围综述。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0126

Judith Zarek, Jinyoung Lee, Deema Harakati, Karen Spitzer, Carl A Laskin, Shinya Ito

{"title":"Vitamin K Antagonists for Pregnant Women With Antiphospholipid Antibodies: A Scoping Review.","authors":"Judith Zarek, Jinyoung Lee, Deema Harakati, Karen Spitzer, Carl A Laskin, Shinya Ito","doi":"10.3899/jrheum.2024-0126","DOIUrl":"10.3899/jrheum.2024-0126","url":null,"abstract":"Objective: To describe characteristics of published research on the safety and efficacy of vitamin K antagonists (VKA) for pregnant patients with antiphospholipid antibodies (aPL), including their methodological characteristics and knowledge gaps.Methods: This study followed the Joanna Briggs Institute methodology for scoping reviews and used the Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews protocol system. Studies were primarily identified through searching electronic databases including MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials. Study characteristics and outcomes were reported and described using customized charting tables.Results: Of 1528 publications, 17 remained in the final analysis. These reported up to 190 VKA-treated aPL-positive pregnancies diagnosed as antiphospholipid syndrome (APS); pregnancy cases were likely overlapping in some publications. In the 17 reports, there were 723 individuals in comparison groups, including healthy pretreatment pregnancies and women with APS treated with standard therapies without VKA. However, only 4 (23.5%) of the 17 publications stated a study objective focusing on VKA use, of which only one was a full-length article. In addition, information on VKA doses, disease diagnostic criteria, and the long-term outcomes of offspring were largely absent.Conclusion: The current evidence is insufficient to assess VKA efficacy and safety profiles in aPL-positive pregnant patients. Studies with a defined focus on VKA use in this population are lacking, and reporting of key information is not consistent. The relative lack of knowledge of VKA use in pregnant women with APS is concerning, and efficacy and safety questions remain.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evidence That Good Life With Osteoarthritis in Denmark (GLA:D), an Exercise and Education Program, Is Beneficial for Osteoarthritis. 有证据表明，丹麦骨关节炎患者的美好生活（GLA:D）--一项运动和教育计划--对骨关节炎有益。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0721

Grace H Lo, Jeffrey B Driban

引用次数: 0

GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis? GRAPPA 观点与反观点：轻度银屑病是否应使用生物制剂？

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0655

Gretchen D Ball, Hassan Hamade, Alice B Gottlieb, Brian Kirby, Kristina Callis Duffin

{"title":"GRAPPA Point-Counterpoint: Should Biologics Be Used for Mild Psoriasis?","authors":"Gretchen D Ball, Hassan Hamade, Alice B Gottlieb, Brian Kirby, Kristina Callis Duffin","doi":"10.3899/jrheum.2024-0655","DOIUrl":"10.3899/jrheum.2024-0655","url":null,"abstract":"Psoriasis (PsO) is commonly classified as mild, moderate, or severe, usually based on body surface area (BSA) or other validated measures. Although most dermatologists agree that mild PsO should be treated with topical therapies, there are circumstances where mild or limited PsO should be treated with biologics, even as first line. A debate about use of topical vs biologic therapy was presented at the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting. Arguments in favor of using biologics when patients have mild disease on limited BSA included presence of psoriatic arthritis (PsA) and symptoms on special sites (ie, scalp, face, body folds, genitals, nails, palms, soles). New data suggest that treating limited or early PsO may decrease the risk of developing PsA. Arguments against using biologics for mild PsO focused on the definition of mild PsO, citing that limited BSA with PsA and significant quality of life impact should not be defined as mild. Truly mild PsO should be treated with topical agents, given their safety and relative low cost. The availability of newer agents like roflumilast and tapinarof have expanded therapeutic choice and have data supporting their use for treatment of special sites.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141876545","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting. GRAPPA 2023 年年会附设 IDEOM 会议报告。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0327

Gretchen D Ball, Danielle Yee, Arianna J Zhang, Lourdes M Perez-Chada, Vibeke Strand, Joseph F Merola, April W Armstrong, Alice B Gottlieb

{"title":"Report of the IDEOM Meeting Adjacent to the GRAPPA 2023 Annual Meeting.","authors":"Gretchen D Ball, Danielle Yee, Arianna J Zhang, Lourdes M Perez-Chada, Vibeke Strand, Joseph F Merola, April W Armstrong, Alice B Gottlieb","doi":"10.3899/jrheum.2024-0327","DOIUrl":"10.3899/jrheum.2024-0327","url":null,"abstract":"The nonprofit organization International Dermatology Outcome Measures (IDEOM) is committed to improving the implementation of patient-centered outcome measures in dermatologic disease. At a conference adjacent to the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2023 annual meeting, the IDEOM Psoriatic Disease Workgroup presented updates on recent efforts in outcome measure advancement. Dr. Alice Gottlieb presented the preliminary findings of a study within the Mount Sinai Health System that aims to determine how well the IDEOM musculoskeletal (MSK) symptom framework, which uses the Psoriasis Epidemiology Screening Tool (PEST) and the Psoriatic Arthritis Impact of Disease (PsAID) instruments, functions in clinical settings. Drs. Joseph Merola and Lourdes Perez-Chada updated attendees on the IDEOM MSK-Q, a 9-item patient-reported questionnaire designed to measure the intensity and impact of MSK symptoms on the quality of life in patients with psoriasis (PsO) with or without psoriatic arthritis (PsA). Dr. Vibeke Strand summarized the Outcome Measures in Rheumatology (OMERACT) 2023 conference sessions. Dr. April Armstrong discussed the preliminary findings of a multicentered study designed to validate the 7-item Dermatology Treatment Satisfaction Instrument (DermSat-7) among patients with PsO. She also introduced the Psoriasis and Psoriatic Arthritis Treatment Satisfaction Instrument, a tool that seeks to capture the level of patient satisfaction with current therapy for PsO and PsA. This report summarizes the developments discussed at the IDEOM PsO and PsA research workgroups during the GRAPPA 2023 annual meeting.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calcium Pyrophosphate Crystals in a Child With Wilson Disease: An Ominous Sign or Incidental Finding? 威尔逊氏病患儿体内的焦磷酸钙结晶：不祥之兆还是偶然发现？

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0086

Sara Bolivar-Wagers, Zachary R Shaheen

引用次数: 0

Stressed Healthcare Systems: The Impact on the Care of Patients With Rheumatic Diseases. 紧张的医疗保健系统：对风湿病患者护理的影响。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0755

Marina Scolnik

引用次数: 0

Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus. 狼疮患者冠状动脉钙化的进展。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0040

Mario C Ocampo-Torres, Gabriela Hernández-Molina, Sergio Criales-Vera, Jorge Sánchez-Guerrero, Pilar Lara-Reyes, Juanita Romero-Díaz

{"title":"Coronary Artery Calcification Progression in Patients With Systemic Lupus Erythematosus.","authors":"Mario C Ocampo-Torres, Gabriela Hernández-Molina, Sergio Criales-Vera, Jorge Sánchez-Guerrero, Pilar Lara-Reyes, Juanita Romero-Díaz","doi":"10.3899/jrheum.2024-0040","DOIUrl":"10.3899/jrheum.2024-0040","url":null,"abstract":"Objective: To evaluate the progression of coronary artery calcification (CAC) and associated risk factors in a systemic lupus erythematosus (SLE) cohort.Methods: We reassessed the presence of CAC in patients with SLE who were screened 9 years before, using multidetector computed tomography. Clinical variables (cumulated disease activity and damage accrual), antiphospholipid syndrome and SLE serology, and cardiovascular (CV) risk factors (hypertension, BMI [kg/m2], modified Framingham risk score, lipid profile, menopausal status) were assessed longitudinally.Results: We included 104 patients from the parent study. Most of them were women (94.2%), with a mean age of 41.0 (SD 8.3) years and mean disease duration of 14.8 (SD 2.9) years. We documented CAC in 17 patients (16.3%). Seven cases were from the parent study and 10 were incident cases. The cumulative incidence of CAC was 9% and the incidence density was 1 per 100 person-years. CAC occurred more frequently in the age groups 30-39 years and 40-44 years. All patients with previous CAC had worsening of their calcium indexes, and none developed clinical CV events. When comparing prevalent CAC cases (n = 17) vs patients without calcification (n = 87), both groups were similar in traditional CV risk factors, disease duration, Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) area under the curve (AUC), and Systemic Lupus International Collaborating Clinics (SLICC) score, but were more likely to be postmenopausal and have higher apolipoprotein B (apoB) levels. Patients with previous CAC had higher apoB levels, SLEDAI-2K AUC scores, and anticardiolipin IgG antibodies than incident cases.Conclusion: CAC in patients with SLE progressed over time but was not associated with adverse CV events during the first 9 years of follow-up. ApoB levels and postmenopausal status might be associated with this progression.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Difficult-to-Treat Concept in Psoriatic Arthritis: Analysis of 2 Potential Definitions in a Large Group of Patients. A Cross-Sectional Study. 银屑病关节炎难以治疗的概念：对一大群患者中两种潜在定义的分析。一项横断面研究。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0101

Fabio Massimo Perrotta, Stefano Gentileschi, Silvia Scriffignano, Riccardo Terribili, Elena Bianchi, Bruno Frediani, Ennio Lubrano

{"title":"Difficult-to-Treat Concept in Psoriatic Arthritis: Analysis of 2 Potential Definitions in a Large Group of Patients. A Cross-Sectional Study.","authors":"Fabio Massimo Perrotta, Stefano Gentileschi, Silvia Scriffignano, Riccardo Terribili, Elena Bianchi, Bruno Frediani, Ennio Lubrano","doi":"10.3899/jrheum.2024-0101","DOIUrl":"10.3899/jrheum.2024-0101","url":null,"abstract":"Objective: The main aim of the study was to evaluate the performance of 2 proposed criteria for difficult-to-treat (D2T) psoriatic arthritis (PsA) in a group of patients and to evaluate the agreement between the 2 sets of criteria.Methods: We performed a cross-sectional analysis of 2 longitudinal cohorts of patients with PsA fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR), with at least 1 year of follow-up. A detailed medical history was collected and a physical examination was performed for all recruited patients. The proposed criteria for patients with D2T PsA were applied in our group. To test the performance of the 2 sets of criteria, we used an external validator (absence of patient acceptable symptom state + physician global assessment ≥ 6 cm). Finally, the agreement between the 2 sets of criteria was assessed.Results: We evaluated 378 patients with PsA (219 male/159 female), with a mean age (range) of 58 (19-75) years. Seventy-five (19.8%) patients fulfilled the D2T criteria proposed by Perrotta et al and 58 (15.3%) the D2T criteria proposed by Kumthekar et al. Both criteria showed comparable performance, with low sensitivity (Perrotta: 37.8%, Kumthekar: 29.7%) but good specificity (Perrotta: 82.1%, Kumthekar: 86.2%). Finally, the agreement between the 2 sets of criteria is substantial (Fleiss [Formula: see text] 0.72), suggesting that both criteria identify nearly the same group of patients.Conclusion: Our study compared 2 published sets of criteria showing comparable performance and substantial agreement. This study may pave the way for further research in this field.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GRAPPA 2023 Patient Research Partner (PRP) Network Update: Enhancing PRP Involvement Within GRAPPA. GRAPPA 2023 年患者研究合作伙伴 (PRP) 网络更新：加强患者研究合作伙伴在 GRAPPA 内的参与。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0267

Arnon Katz, Maarten de Wit, Christine Lindsay

引用次数: 0

Validation of Different Dementia Code-Based Definitions in a Population-Based Study of Rheumatoid Arthritis. 类风湿关节炎人群研究中不同痴呆症代码定义的验证。

IF 3.6 2区医学

Journal of Rheumatology Pub Date : 2024-10-01 DOI: 10.3899/jrheum.2024-0299

Maria Vassilaki, Roslin Jose George, Rakesh Kumar, Edward Lovering, Sara J Achenbach, Suzette J Bielinski, Jennifer St Sauver, John M Davis, Cynthia S Crowson, Elena Myasoedova

{"title":"Validation of Different Dementia Code-Based Definitions in a Population-Based Study of Rheumatoid Arthritis.","authors":"Maria Vassilaki, Roslin Jose George, Rakesh Kumar, Edward Lovering, Sara J Achenbach, Suzette J Bielinski, Jennifer St Sauver, John M Davis, Cynthia S Crowson, Elena Myasoedova","doi":"10.3899/jrheum.2024-0299","DOIUrl":"10.3899/jrheum.2024-0299","url":null,"abstract":"Objective: Rheumatoid arthritis (RA) has been associated with an elevated dementia risk. This study aimed to examine how different diagnostic dementia definitions perform in patients with RA compared to individuals without RA.Methods: The study population included 2050 individuals (1025 with RA) from a retrospective, population-based cohort in southern Minnesota and compared the performance of 3 code-based dementia diagnostic algorithms with medical record review diagnosis of dementia. For the overall comparison, each patient's complete medical history was used, with no time frames. Sensitivity analyses were performed using 1-, 2-, and 5-year windows around the date that dementia was identified in the medical record (reference standard).Results: Algorithms performed very similarly in persons with and without RA. The algorithms generally had high specificity, negative predictive values, and accuracy, regardless of the time window studied (> 88%). Sensitivity and positive predictive values varied depending on the algorithm and the time window. Sensitivity values ranged 56.5-95.9%, and positive predictive values ranged 55.2-83.1%. Performance measures declined with more restrictive time windows.Conclusion: Routinely collected electronic health record (EHR) data were used to define code-based dementia diagnostic algorithms with good performance (vs diagnosis by medical record review). These results can inform future studies that use retrospective databases, especially in the same or a similar EHR infrastructure, to identify dementia in individuals with RA.","PeriodicalId":50064,"journal":{"name":"Journal of Rheumatology","volume":null,"pages":null},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11444897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0